Page 122 - 2019_01-Haematologica-web

Y. Lu et al.
fuses the retinoic acid receptor alpha gene
to a novel transcribed locus. Nature. 1990;
347(6293):558-561.
18. Dos Santos GA, Kats L, Pandolfi PP.
Synergy against PML-RARa: targeting tran- scription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793- 2802.
19. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89(9):3345-3353.
20. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354- 3360.
21. Sanz MA, Fenaux P, Lo Coco F. Arsenic tri- oxide in the treatment of acute promyelo- cytic leukemia. A review of current evi- dence. Haematologica. 2005;90(9):1231- 1235.
22. Girmenia C, Lo Coco F, Breccia M, et al. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia. 2003;17(5):925-930.
23. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syn- drome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99(3):822-824.
24. Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014; 370(19):1864-1866.
25. Lehmann-Che J, Bally C, de The H. Resistance to therapy in acute promyelo- cytic leukemia. N Engl J Med. 2014; 371(12):1170-1172.
26. Chendamarai E, Ganesan S, Alex AA, et al. Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS One. 2015;10(3):e0121912.
27. Lyu Y, Lou J, Yang Y, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and - independent pathways. Leukemia. 2017;31(12):2543-2551.
28. Wang X, Lin Q, Lv F, et al. LG-362B targets PML-RARalpha and blocks ATRA resist- ance of acute promyelocytic leukemia. Leukemia. 2016;30(7):1465-1474.
29. Liu CX, Yin QQ, Zhou HC, et al. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol. 2012;8(5):486-493.
30. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA. 1997;94(6):2551-2556.
31. Tong Q, You H, Chen X, et al. ZYH005, a novel DNA intercalator, overcomes all- trans retinoic acid resistance in acute promyelocytic leukemia. Nucleic Acids
Res. 2018;46(7):3284-3297.
32. Bachmann AS, Opoku-Ansah J, Ibarra-
Rivera TR, et al. Syrbactin structural analog TIR-199 blocks proteasome activity and induces tumor cell death. J Biol Chem. 2016;291(16):8350-8362.
33. Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood. 2000; 95(5):1541-1550.
34. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degrada- tion of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA. 1999;96(26):14807-14812.
35. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature. 1990;343(6254):177-180.
36. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interfer- on regulatory factor-1 gene expression in myeloid cells. Blood. 1996;88(1):114-123.
37. Yu M, Tong JH, Mao M, et al. Cloning of a gene (RIG-G) associated with retinoic acid- induced differentiation of acute promyelo- cytic leukemia cells and representing a new member of a family of interferon-stimulat- ed genes. Proc Natl Acad Sci USA. 1997;94(14):7406-7411.
38. Davies PJ, Murtaugh MP, Moore WT, Jr., Johnson GS, Lucas D. Retinoic acid- induced expression of tissue transglutami- nase in human promyelocytic leukemia (HL-60) cells. J Biol Chem. 1985; 260(8):5166-5174.
39. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2002;99(6):3806-3811.
40. Koeffler HP, Ranyard J, Pertcheck M. Myeloperoxidase: its structure and expres- sion during myeloid differentiation. Blood. 1985;65(2):484-491.
41. Gianni M, Li Calzi M, Terao M, et al. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood. 1996; 87(4):1520-1531.
42. Toma S, Isnardi L, Raffo P, et al. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer. 1998;78(1):86-94.
43. Martinez Molina D, Jafari R, Ignatushchenko M, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341(6141):84-87.
44. Jafari R, Almqvist H, Axelsson H, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9(9):2100-2122.
45. Huang DL, Bax NA, Buckley CD, Weis WI, Dunn AR. Vinculin forms a directionally asymmetric catch bond with F-actin.
Science. 2017;357(6352):703-706.
46. Xia L, Wang XR, Wang XL, et al. A novel role for pyruvate kinase M2 as a corepres- sor for P53 during the DNA damage response in human tumor cells. J Biol
Chem. 2016;291(50):26138-26150.
47. Panchabhai S, Schlam I, Sebastian S, Fonseca R. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.
Leukemia. 2017;31(4):991-994.
48. Gu ZM, Wu YL, Zhou MY, et al. Pharicin B
stabilizes retinoic acid receptor-alpha and presents synergistic differentiation induc- tion with ATRA in myeloid leukemic cells. Blood. 2010;116(24):5289-5297.
49. Li K, Wang F, Cao WB, et al. TRIB3 pro- motes APL progression through stabiliza- tion of the oncoprotein PML-RARalpha and inhibition of p53-mediated senescence. Cancer Cell. 2017;31(5):697-710 e697.
50. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov. 2007;6(10):793-810.
51. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML- RARalpha oncoprotein by directly binding PML. Science. 2010;328(5975):240-243.
52. Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocyt- ic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol. 1997;17(8):4859-4869.
53. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood. 1999;93(5):1477-1481.
54. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, Garattini E. Tyrosine kinase inhibitor STI571 potentiates the pharmaco- logic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML- RARalpha. Blood. 2001;97(10):3234-3243.
55. Finch RA, Li J, Chou TC, Sartorelli AC. Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid-treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation. Blood. 2000; 96(6):2262-2268.
56. Launay S, Gianni M, Diomede L, Machesky LM, Enouf J, Papp B. Enhancement of ATRA-induced cell differ- entiation by inhibition of calcium accumu- lation into the endoplasmic reticulum: cross-talk between RAR alpha and calcium- dependent signaling. Blood. 2003; 101(8):3220-3228.
57. Witcher M, Shiu HY, Guo Q, Miller WH, Jr. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood. 2004;104(10):3335-3342.
112
haematologica | 2019; 104(1)